Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Total Liabilities (2016 - 2025)

vTv Therapeutics (VTVT) has disclosed Total Liabilities for 12 consecutive years, with $25.5 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 6.25% to $25.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.5 million through Dec 2025, up 6.25% year-over-year, with the annual reading at $25.5 million for FY2025, 6.25% up from the prior year.
  • Total Liabilities hit $25.5 million in Q4 2025 for vTv Therapeutics, down from $29.0 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $29.6 million in Q2 2022 to a low of $8.4 million in Q3 2021.
  • Historically, Total Liabilities has averaged $22.9 million across 5 years, with a median of $25.7 million in 2024.
  • Biggest five-year swings in Total Liabilities: tumbled 44.61% in 2021 and later soared 233.11% in 2022.
  • Year by year, Total Liabilities stood at $10.3 million in 2021, then skyrocketed by 167.26% to $27.4 million in 2022, then rose by 7.91% to $29.6 million in 2023, then decreased by 18.95% to $24.0 million in 2024, then grew by 6.25% to $25.5 million in 2025.
  • Business Quant data shows Total Liabilities for VTVT at $25.5 million in Q4 2025, $29.0 million in Q3 2025, and $24.0 million in Q2 2025.